New Issue!
The Latest
Remdesivir may offer kidney, CV benefits for transplant recipients with acute COVID-19
Doctors warn of very serious Vibrio infection spreading in Chesapeake Bay
Early Remdesivir May Protect Kidney Transplants After COVID-19: Nitipong Permpalung, MD, MPH
COVID Study Supports Antiviral Use in Kidney Transplant Recipients
Remdesivir for COVID-19 linked to better outcomes for adult kidney transplant recipients
Biofilms and specific bacteria in colorectal cancer development, with Prof. Cynthia L. Sears, MD
Maryland cyclosporiasis cases spike, part of a national surge in intestinal illness cases
When Will Cyclospora Outbreak End? It Could Be Weeks
High Suspicion for Cyclosporiasis Warranted Even as Investigation Continues
Fact Check: No evidence that ivermectin can treat Cyclospora infections
Why the tick population is increasing--and diseases are spreading--in different areas
Pools, Splash Pads May Help Spread Diarrhea Outbreak, Experts Warn
U.S. death rate falls to its lowest point on record
Vaccines, antibody shots, and pills: How scientists are trying to prevent tick-borne diseases
So You Found a Tick on You. Here's Exactly What to Do Next
Are Drug‑Resistant Infections Outpacing Industry Efforts?
Live with a partner? You may be sharing more microbes than you think
Syphilis: Two Steps Forward, One Step Back
Ebola vaccine for Bundibugyo strain could take months before human trials
What to know about the Ebola outbreak
11 TV Hill: Johns Hopkins Medicine expert answers questions about hantavirus
How the bacteria in your gut could raise colon cancer risk
At last, a pill that can prevent COVID after exposure to infected people
Johns Hopkins Medicine doctor shares Hantavirus concerns with 2 Marylanders being monitored
6 tick-borne diseases that should be on your radar
Are Cruises Still Safe After Deadly Hantavirus Outbreak? What To Know
Scientists pinpoint how toxic bacteria in the gut causes colon cancer - as disease surges in under 50s
What Travelers Should Know About the Hantavirus Outbreak on a Cruise Ship
Syphilis making a comeback, health officials warn. CDC map shows where risk is highest
news releases & original stories Hopkins Headliners
-
Remdesivir for COVID-19 Linked to Better Outcomes for Adult Kidney Transplant Recipients
2028-07-28 | Johns Hopkins Medicine News Release | Nate Permpalung
-
Cyclosporiasis Outbreak 2026 Expert Q&A
2026-07-14 | Johns Hopkins Medicine | Cynthia Sears
-
Most cases of HIV persistence in blood following treatment explained by defective copies of the virus
2026-06-08 | Johns Hopkins Medicine News Release | Francesco Simonetti
-
Solving a 15 Year Mystery Scientists Discover How Gut Bacteria Toxin Invades Colon Cells to Trigger Cancer
2026-05-07 | Johns Hopkins Medicine News Release | Cynthia Sears
-
Hopkins Infectious Disease Expert on Why Science Diplomacy Matters Today
2026-04-29 | Johns Hopkins University Bloomberg Center | Amita Gupta
-
10 Insights from the 2026 Science Diplomacy Summit
2026-04-22 | Johns Hopkins University Bloomberg Center | Amita Gupta
-
Johns Hopkins Team Develops Therapeutic, Nasally Delivered DNA Vaccine for Tuberculosis
Research shows the vaccine — in combination with drug therapy — accelerated a relapse-free TB cure in mice, improved activity of a drug-resistant TB regimen and stimulated immune responses in nonhuman primates
-
Screening And Preventive Treatment Program Reduced Tuberculosis Incidence 83% Among Tibetan Children Living in Northern India
Study conducted partially with federal funds shows a comprehensive effort can achieve rapid and sustained reduction of disease transmission and impact in high TB burden areas using existing control measures
-
Five Johns Hopkins Medicine Researchers Named Fellows of the American Association for the Advancement of Science
Dr. Noreen Hynes is among the 2025 class of fellows.
-
Johns Hopkins Medicine-led consortium receives $24 million federal grant to find hepatitis B cure
The Johns Hopkins Medicine-led, multinational Hepatitis B and HIV Cure Consortium was recently established through the awarding of a five-year, $24 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).
-
One Versus Three: Federally Funded Clinical Trial Shows Daily Meds for a Month Comparable to Once Weekly for Three Months to Treat TB
Clinical trial shows a 1-month regimen to treat latent tuberculosis infection is noninferior to 3-month course
-
Federally Funded Clinical Trial Suggests Knowing HIV ‘Viral Load’ Doesn’t Improve Number of Patients Seeking Needed Care
A federally funded clinical trial suggests knowing HIV viral load (number of HIV particles in the body) doesn’t improve the number of patients seeking treatment for active HIV infection or preventive care if uninfected, but at high risk of becoming infected.
